ArticleIn silico pharmacology2025
Leveraging immunoinformatic for the rational design of highly immunogenic multi-epitope subunit vaccines against Dugbe virus: a molecular docking and simulation approach.
Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immunoinformatic based Development of a Multi-Epitope Precision Vaccine Targeting Glycoprotein and RdRp of Oropouche Virus:Saudi medical journal · 2026Article
- Immunometabolic programming of macrophages and tumor-associated macrophages: metabolic pathways shaping polarization, immune regulation, and disease outcomes.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Dugbe virus is a tick-borne virus that poses a serious risk to cattle and human' health and belongs to the Orthonairovirus genus. Given the pressing public health threat posed by Dugbe virus infection and the absence of targeted vaccines or antiviral medications, the innovative immunoinformatic techniques were employed to design potent vaccine. The strategy of this study involves screening the envelopment polyprotein, Nucleoprotein, and RNA-dependent RNA polymerase to predict immunogenic HTL, CTL, and B cell epitopes. Predicted epitopes were modeled in 3D structure and validated for stability via molecular dynamics. Docking and immune simulations were used to asses vaccine-TLR3 interactions and immune response. To construct a multiepitope vaccine candidate, the chosen epitopes were linked together and subjected to 3D modeling. The molecular docking analysis confirmed the strong binding affinity between the constructed vaccine and human TLR8. Notably, a 500 ns molecular dynamics simulation further confirmed the robust stability and proper folding of the vaccine-TLR8 complex. The constructed vaccine demonstrated stable expression in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.